The biotech's Phase 2a study of bempikibart showed a 35.3% mean reduction in hair loss scores, with the company planning a ...

The trial enrolled 33 patients with severe or very severe forms of AA, most with baseline SALT scores between 50 and 100.

Nearly two years after clinical setbacks cratered Q32’s stock price, new results showed hair growth improvements that ...

Q32 Bio (NASDAQ:QTTB) reported positive 36-week top-line results from Part B of its SIGNAL-AA Phase 2a clinical trial ...

Phase 2 Data Boosts Investor Confidence Q32 Bio Inc. (NASDAQ:QTTB) shares surged 60% on Monday after the biotechnology ...

Shares of Q32 Bio (NASDAQ: QTTB) soared on Monday after the biotechnology company announced promising clinical trial results ...

Waking up to find clumps of hair on your pillow or discovering smooth, round patches where thick hair once grew can be absolutely devastating. This jarring experience affects millions of people ...

A medication that has been found to effectively treat the skin disease alopecia areata in adults is also successful in treating adolescent patients, according to a Yale-led clinical trial. Alopecia ...

Shamsha Damani has lived with alopecia areata since she was six, which turned into alopecia universalis in 2013. She's a fierce advocate for those with alopecia areata and currently serves on the ...